November 01, 2023 (Earnings Report) Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Shopify
Symbol: SHOP
Recent Price: $47.19
Average Analyst Price Target: $65.00 (42.25%)
Market Cap: $56.47B
Last Year's EPS: 0.01
Consensus EPS Forecast: 0.06
Expected Earnings Date: 2023-08-02
Recent Analyst Action: Darren Aftahi, analyst at Roth MKM, reiterates coverage on Shopify (SHOP) in the Technology sector with a Buy rating and a price target of $68 (1 day ago).
TipRanks.com also reports that Shopify currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $65.00 . The target pricing ranges from a high forecast of $75 down to a low forecast of $55. Shopify (SHOP)’s last closing price was $47.19 which would put the average price target at 42.25% upside.Here are 3rd party ratings for SHOP:
Recent Analyst Action: Jonathan Block, analyst at Stifel Nicolaus, reiterates coverage on Zoetis (ZTS) in the Healthcare sector with a Buy rating and a price target of $195 (1 day ago).
TipRanks.com also reports that Zoetis currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $209.60 . The target pricing ranges from a high forecast of $230 down to a low forecast of $195. Zoetis (ZTS)’s last closing price was $157 which would put the average price target at 40.61% upside.Here are 3rd party ratings for ZTS:
Recent Analyst Action: Tyler Van, analyst at TD Cowen, reiterates coverage on Moderna (MRNA) in the Healthcare sector with a Hold rating and a price target of $100 (6 days ago).
TipRanks.com also reports that Moderna currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $129.25 . The target pricing ranges from a high forecast of $64 down to a low forecast of $100. Moderna (MRNA)’s last closing price was $75.96 which would put the average price target at 113.27% upside.Here are 3rd party ratings for MRNA:
Recent Analyst Action: William Plovanic, analyst at Canaccord Genuity, reiterates coverage on Insulet (PODD) in the Healthcare sector with a Buy rating and a price target of $355 (1 week ago).
TipRanks.com also reports that Insulet currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $241.75 . The target pricing ranges from a high forecast of $355 down to a low forecast of $162. Insulet (PODD)’s last closing price was $132.57 which would put the average price target at 86.41% upside.Here are 3rd party ratings for PODD:
Recent Analyst Action: Roanna Ruiz, analyst at Leerink Partners, reiterates coverage on Lantheus (LNTH) in the Healthcare sector with a Buy rating and a price target of $125 (1 week ago).
TipRanks.com also reports that Lantheus currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $118.80 . The target pricing ranges from a high forecast of $130 down to a low forecast of $100. Lantheus (LNTH)’s last closing price was $64.60 which would put the average price target at 82.40% upside.Here are 3rd party ratings for LNTH:
Recent Analyst Action: Mayank Mamtani, analyst at B.Riley Financial, reiterates coverage on Denali Therapeutics (DNLI) in the Healthcare sector with a Buy rating and a price target of $37.99 (1 day ago).
TipRanks.com also reports that Denali Therapeutics currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $60.75 . The target pricing ranges from a high forecast of $50 down to a low forecast of $105. Denali Therapeutics (DNLI)’s last closing price was $18.83 which would put the average price target at 160.22% upside.Here are 3rd party ratings for DNLI:
Recent Analyst Action: Tazeen Ahmad, analyst at Bank of America Securities, reiterates coverage on Prothena (PRTA) in the Healthcare sector with a Buy rating and a price target of $70 (5 days ago).
TipRanks.com also reports that Prothena currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $76.75 . The target pricing ranges from a high forecast of $94 down to a low forecast of $60. Prothena (PRTA)’s last closing price was $36.46 which would put the average price target at 136.34% upside.Here are 3rd party ratings for PRTA:
To Your Financial Future,
The Editor, WallStreetSectors.com